MAGL(单酰甘油脂肪酶)抑制剂在实验性缺血性卒中中的神经保护作用
研究在三种局灶性脑缺血实验模型中,于缺血后60分钟给予选择性MAGL抑制剂JZL184或MJN110,发现药物显著减轻梗死体积和半球肿胀,改善感觉运动缺陷,抑制炎症反应并减少变性神经元数量;大麻素受体拮抗剂不能完全抵消这些效应,提示抗炎作用源于抑制类花生酸生成而非激活大麻素受体。
要点
- 缺血后60分钟给予MAGL抑制剂可减轻实验性局灶性脑缺血的梗死体积和半球肿胀。
- MAGL抑制剂改善感觉运动缺陷,抑制炎症反应,减少变性神经元数量。
- 大麻素受体拮抗剂不能完全抵消MAGL抑制剂的获益,提示作用经抑制类花生酸生成而非大麻素受体激活。
核心结论
- 结果提示MAGL可能参与局灶性脑缺血的病理生理过程,是有前景的缺血性卒中治疗靶点。
研究设计与样本
- 在自发性高血压大鼠(SHR)和血压正常的WKY(Wistar Kyoto)大鼠上建立三种局灶性脑缺血模型:皮质内注射强效血管收缩剂内皮素-1、经颅骨切开永久闭塞大脑中动脉远端段、或经腔内线栓法短暂闭塞大脑中动脉。
- 于局灶性脑缺血后60分钟给予JZL184或MJN110,在第1至28天通过磁共振成像、组织学和行为学测试评估梗死体积、半球肿胀和功能结局。
主要发现
- 药理学抑制MAGL显著减轻梗死体积和半球肿胀。
- MAGL抑制改善感觉运动缺陷、抑制炎症反应并减少变性神经元数量。
- 选择性大麻素受体拮抗剂不能完全抵消MAGL抑制的有益效应,表明抗炎效应源于抑制类花生酸生成而非激活大麻素受体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: MAGL (monoacylglycerol lipase) is an enzyme that hydrolyzes the endocannabinoid 2-arachidonoylglycerol and regulates the production of arachidonic acid and prostaglandins-substances that mediate tissue inflammatory response. Here, we have studied the effects of the selective MAGL inhibitors JZL184 and MJN110 and their underlying molecular mechanisms on 3 different experimental models of focal cerebral ischemia. METHODS: SHR (spontaneously hypertensive rats) and normotensive WKY (Wistar Kyoto) rats were subject to an intracortical injection of the potent vasoconstrictor endothelin-1, permanent occlusion of a distal segment of the middle cerebral artery via craniectomy, or transient occlusion of the middle cerebral artery by the intraluminal suture method. JZL184 or MJN110 was administered 60 minutes after focal cerebral ischemia. Infarct volumes, hemispheric swelling, and functional outcomes were assessed between days 1 to 28 by magnetic resonance imaging, histology, and behavioral tests. RESULTS: Pharmacological inhibition of MAGL significantly attenuated infarct volume and hemispheric swelling. MAGL inhibition also ameliorated sensorimotor deficits, suppressed inflammatory response, and decreased the number of degenerating neurons. These beneficial effects of MAGL inhibition were not fully abrogated by selective antagonists of cannabinoid receptors, indicating that the anti-inflammatory effects are caused by inhibition of eicosanoid production rather than by activation of cannabinoid receptors. CONCLUSIONS: Our results suggest that MAGL may contribute to the pathophysiology of focal cerebral ischemia and is thus a promising therapeutic target for the treatment of ischemic stroke.
引用
- Choi SH, Arai AL, Mou Y, et al. Neuroprotective Effects of MAGL (Monoacylglycerol Lipase) Inhibitors in Experimental Ischemic Stroke. Stroke. 2018. PMID: 29440474. doi:10.1161/STROKEAHA.117.019664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。